跳至主要内容
临床试验/NCT05254366
NCT05254366已完成不适用

A Domestic, Prospective, Non-interventional Study of Remazolam Methyl Benzene Sulfonic Acid for Injection in Real-world Clinical Practice

Jiangsu HengRui Medicine Co., Ltd.1 个研究点 分布在 1 个国家目标入组 2,022 人开始时间: 2022年1月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
2,022
试验地点
1
主要终点
Adverse events

研究概览

简要总结

This is a non-interventional study of remazolam toluenesulfonate (rebenin ®) for injection in Chinese patients. A total of 2000 patients were enrolled in this study based on the preliminary safety assessment of rebenin ®, and all safety information was obtained

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Use rebenin ® for painless gastroscopic sedation and painless colonoscopic sedation
  • Patients need to sign informed consent

排除标准

  • Patients who are participating in or planning to participate in any interventional clinical trial
  • The investigator considers that there are any other reasons for the patient's ineligibility for the study

研究组 & 干预措施

Cohort 1

Painless gastroscopic sedation cohort

干预措施: Remimazolam Tosilate for Injection (Drug)

Cohort 2

Painless colonoscopy sedation cohort

干预措施: Remimazolam Tosilate for Injection (Drug)

结局指标

主要结局

Adverse events

时间窗: Within 3 days of receiving gastroscopy and colonoscopy

Use adverse event record form,Refer to version 5.0 of the NCI-CTCAE

次要结局

  • Serious adverse events(Within 3 days of receiving gastroscopy and colonoscopy)
  • Adverse drug reactions(Within 3 days of receiving gastroscopy and colonoscopy)
  • Injection pain questionnaire(Within 3 days of receiving gastroscopy and colonoscopy)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验